Authors:
Dumontet, C
Morschhauser, F
Solal-Celigny, P
Bouafia, F
Bourgeois, E
Thieblemont, C
Leleu, X
Hequet, O
Salles, G
Coiffier, B
Citation: C. Dumontet et al., Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma, BR J HAEM, 113(3), 2001, pp. 772-778
Authors:
Morschhauser, F
Cayuela, JM
Martini, S
Baruchel, A
Rousselot, P
Socie, G
Berthou, P
Jouet, JP
Straetmans, N
Sigaux, F
Fenaux, P
Preudhomme, C
Citation: F. Morschhauser et al., Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients, J CL ONCOL, 18(4), 2000, pp. 788-794
Authors:
Brice, P
Divine, M
Simon, D
Coiffier, B
Leblond, V
Simon, M
Voilat, L
Devidas, A
Morschhauser, F
Rohrlich, P
Andre, M
Lepage, E
Ferme, C
Citation: P. Brice et al., Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD), ANN ONCOL, 10(12), 1999, pp. 1485-1488
Authors:
Leclercq, I
Mortreux, F
Morschhauser, F
Duthilleul, P
Desgranges, C
Gessain, A
Cavrois, M
Vernant, JP
Hermine, O
Wattel, E
Citation: I. Leclercq et al., Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia lymphoma (ATLL), BR J HAEM, 105(3), 1999, pp. 743-751